Background Human papillomavirus (HPV) immunisation with a bivalent vaccine (Cervarix)
was introduced in England, UK, in Sept 1, 2008: routine vaccination was offered to girls …

Objective To estimate the health impact, financial costs, and cost‐effectiveness of scaling‐up
coverage of human papillomavirus (HPV) vaccination (young girls) and cervical cancer …

Background Funding for human papillomavirus (HPV) vaccination in Japan began in 2010
for girls aged 12–16 years, with three-dose coverage initially reaching more than 70%. On …

Cervical cancer is a leading cause of cancer death among women in low-income countries,
with∼ 25% of cases worldwide occurring in India. We estimated the potential health and …

Eastern Africa has the world's highest cervical cancer incidence and mortality rates. We
used epidemiologic data from Kenya, Mozambique, Tanzania, Uganda, and Zimbabwe to …

Background Introduction of human papillomavirus (HPV) vaccination in settings with the
highest burden of HPV is not universal, partly because of the absence of quantitative …

Comprehensive evaluation of the cost-effectiveness of HPV vaccination in China has not
previously been performed. The objective of this study was to evaluate vaccination as an …

Background Mortality rates from cervical cancer demonstrate deep inequality in health
between richer and poorer populations. Over 310 000 women died of this preventable …

Abstract In 2020, the World Health Organization launched a major initiative to eliminate
cervical cancer globally. The initiative is built around the three key pillars of human …

Cervical cancer is the fourth most common cancer among women globally, with an
estimated 570 000 new cases and 311 000 deaths worldwide in 2018. 1–3 The highest …